Investors of Capricor Therapeutics Face Potential Losses Amid Securities Fraud Allegations

Investors Urged to Step Forward

In light of recent developments, investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) are encouraged to assess their financial standing and consider joining a class action lawsuit. Led by the law firm Hagens Berman, this legal action arises from significant allegations of securities fraud that potentially affected many stakeholders involved with the company.

Background on the Allegations

The class action lawsuit cites false and misleading statements made by Capricor's executives regarding the clinical trial data and regulatory processes surrounding the company’s lead candidate, Deramiocel. Intended to treat Duchenne muscular dystrophy (DMD), the claims have drawn scrutiny after the company seemed to modify its statistical analysis plan (SAP) without regulatory agreement from the U.S. Food and Drug Administration (FDA).

On December 3, 2025, Capricor released what was hailed as 'positive topline results' from the pivotal Phase 3 HOPE-3 study of Deramiocel, leading to a meteoric rise in stock value by 370% in a single day. However, this optimism was shattered when the FDA later questioned the veracity of these claims, leading to a considerable decline in share value. As the lawsuit indicates, the FDA's briefing document revealed that the HOPE-3 study failed to meet its predetermined efficacy benchmarks, contradicting Capricor's previous assertions about the drug’s efficacy.

Timeline of Critical Events

Investors were led to believe in the potential of Deramiocel, only to face dramatic market repercussions when the FDA's report became public. On July 27, 2026, in the wake of the FDA's revelations, Capricor's stock plummeted by around 64%, closing at $7. This drastic decline underscores the substantial losses experienced by shareholders and places greater urgency on seeking legal recourse.

Hagens Berman has set a lead plaintiff deadline for the case on September 28, 2026, which means that affected investors have a limited window to participate in the class action. The firm urges anyone who suffered losses between December 17, 2025, and July 26, 2026, to step forward. To share in any potential recovery, one does not necessarily need to seek lead plaintiff status, making this a potentially less daunting option for those impacted.

Seeking Justice and Recovering Losses

For individuals who invested in Capricor and subsequently faced financial hardships as a result of these developments, this lawsuit may offer a path to seek restitution for losses incurred due to alleged misleading actions by the firm's leadership. Hagens Berman emphasizes that its focus remains squarely on uncovering the full nature of the alleged misrepresentation and providing investors with avenues for recovery.

Additionally, the firm is also appealing to whistleblowers who may have non-public information that could shed light on the situation. Such individuals could also explore options available through the SEC whistleblower program, which offers financial rewards for pertinent information leading to recoveries.

About Hagens Berman

Hagens Berman is a formidable presence in the legal landscape, with a track record of handling complex litigation and advocating for the rights of investors and consumers alike. They have recovered over $2.9 billion for their clients in various cases involving corporate misconduct. The firm's commitment to transparency and justice for harmed parties is more relevant now than ever in the wake of the Capricor situation.

For affected investors seeking to explore their legal options, additional resources and information can be found at Hagens Berman’s dedicated webpage. The clock is ticking to take action in a case that could shape the future of not just Capricor, but investor protections related to pharmaceutical disclosures and practices.